VSBC Stock Overview
VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VitaSpring Biomedical Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.00 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$10.00 |
| Beta | 1.39 |
| 11 Month Change | 0% |
| 3 Month Change | 36.24% |
| 1 Year Change | 2.74% |
| 33 Year Change | 37.61% |
| 5 Year Change | n/a |
| Change since IPO | 3,471.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| VSBC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | 2.7% | 16.1% | 31.6% |
Return vs Industry: VSBC exceeded the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: VSBC underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| VSBC volatility | |
|---|---|
| VSBC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VSBC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VSBC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Richard Chu | www.vitaspringbio.com |
VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 2020.
VitaSpring Biomedical Co. Ltd. Fundamentals Summary
| VSBC fundamental statistics | |
|---|---|
| Market cap | US$3.11b |
| Earnings (TTM) | US$935.61k |
| Revenue (TTM) | US$4.98m |
3,319x
P/E Ratio623.7x
P/S RatioIs VSBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSBC income statement (TTM) | |
|---|---|
| Revenue | US$4.98m |
| Cost of Revenue | US$2.95m |
| Gross Profit | US$2.03m |
| Other Expenses | US$1.09m |
| Earnings | US$935.61k |
Last Reported Earnings
Oct 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0045 |
| Gross Margin | 40.75% |
| Net Profit Margin | 18.79% |
| Debt/Equity Ratio | 0% |
How did VSBC perform over the long term?
See historical performance and comparison